Epigenetic synthetic lethality approaches in cancer therapy

Area of Science:

• Oncology
• Epigenetics
• Cancer Therapeutics

Background:

• Malignant tumor development is linked to epigenetic modifications, a significant research area.
• Epigenetic regulators and inhibitors exist, yet their effectiveness in solid tumors is often inadequate.
• Synthetic lethality has emerged as a promising therapeutic strategy, highlighted by PARP inhibitors in BRCA1-mutated ovarian cancer.

Purpose of the Study:

• To review epigenetic-related synthetic lethal mechanisms.
• To explore therapeutic strategies targeting epigenetic alterations in cancer.

Main Methods:

• Review of high-throughput screening data using CRISPR-Cas9 and shRNA technology.
• Analysis of identified synthetic lethal pairs involving epigenetic genes.

Main Results:

• Numerous synthetic lethal pairs involving epigenetic regulators (e.g., SWI/SNF, PRC2, SETD2, KMT2C, MLL fusions) have been identified.
• Focus on three key synthetic lethality categories: epigenetic mutations with epigenetic inhibitors, epigenetic mutations with non-epigenetic inhibitors, and oncogene mutations with epigenetic inhibitors.

Conclusions:

• Epigenetic-related synthetic lethality presents a promising avenue for novel cancer therapies.
• Understanding these mechanisms can guide the development of more effective treatments for solid tumors.